Key facts
- This page summarizes Michael Halstead's Form 4 filing for Intra-Cellular Therapies, Inc. (ITCI).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 04 Mar 2025, 18:01.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
Tax liability
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Additional SEC filing notes
Footnote F1
Restricted stock units convert into common stock on a one-for-one basis.
Footnote F2
Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units and does not represent a sale by the reporting person.
Footnote F3
Each restricted stock unit represents a contingent right to receive one share of common stock.
Footnote F4
On March 1, 2024, the reporting person was granted 36,717 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.